ClinicalTrials.gg
Not yet recruitingNCT07645326RISK-ADAPTUpdated Oct 6, 2026

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

A Phase 2 interventional study of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) in Metastatic Hormone-sensitive Prostate Cancer (mHSPC), sponsored by Georgetown University. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Georgetown University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 6, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Planned enrollment
43rd of 185
108 · median 39
Started
2026
with 6 others
Phase 2
104 of 193
4 open now
Primary completion
2032-08
later than 23 of 23 live
Registered
191st of 193
by date

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 43rd largest by planned enrollment of the 185 interventional ones that give a count, is one of 7 that started in 2026, is one of 104 in phase 2, reaches primary completion later than 23 of the 23 other live ones, and was the 191st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, interventional, non-randomized, phase 2 study to assess oncologic outcomes of metastatic hormone-sensitive prostate cancer (mCSPC) patients who receive a risk-adapted treatment approach followed by treatment de-escalation at the Medstar Health network. A pragmatic design will be implemented in order to make the study available to patients at greatest needs from minority populations in the community. Additional assessments include quality-of-life (QoL) and sexual function changes as well as correlative studies. A maximum of 108 patients will be enrolled in this study. The investigators hypothesize that with a risk-adapted treatment approach followed by treatment de-escalation, more than 50% of patients will have radiographic progression-free survival (rPFS) at 36 months. Additionally, the investigators hypothesize that the risk-stratified de-escalation approach will result in fewer treatment-related adverse events and better QoL, compared to historical controls.

03

Conditions studied

  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients with castrate sensitive prostate cancer that are eligible for standard of care (SOC) per treating physician.

    a. Low risk SOC: ADT + ARPI + radiation to the prostate i. For patients with low-risk disease (defined in Section 8.1), prior treatment with ADT or ARPI for up to 8 weeks for mCSPC is permitted; however, prior treatment with docetaxel is not allowed.

    b. High risk SOC: ADT + ARPI +/- docetaxel i. For patients with high-risk disease (defined in Section 8.1), prior treatment with ADT, ARPI, or docetaxel for up to 8 weeks for mCSPC is permitted.

  2. Patients who can give and are willing to comply with follow-up visits and treatment plans.

Exclusion criteria

Exclusion Criteria:

  1. Patients for whom, in the opinion of the investigator, participation in the study, use of the drugs outlined in the study, or use of the risk-adapted treatment de-escalation strategy is not appropriate or safe.
  2. Patients who have received prior treatment with any of the following:

    1. Chemotherapy other than docetaxel for prostate cancer any time prior to enrollment;
    2. Radiopharmaceuticals for prostate cancer any time prior to enrollment.
  3. Patients who have received treatment with radiotherapy (EBRT, brachytherapy, or radiopharmaceuticals) within 2 weeks before prior to the start of study treatment.
  4. Patients with prior treatment with an ARPI for non- disease within 6 months of diagnosis of metastatic disease are not eligible.

    a. Note: Patients who were diagnosed with metastatic disease or more than 6 months after treatment with an ARPI non-metastatic disease are eligible.

  5. Patients who had previous (within 28 days before the start of study drug or 4 half-lives of the treatment of the previous study, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s).
  6. Patients with an inability to swallow oral medications in the opinion of the clinical investigator.
  7. Patients with .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Low Risk Prostate Cancer

    Low risk patients will receive 6-month doublet therapy with Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitor (ARPI) + prostate radiation with or without radiation to metastatic sites followed by 30 months ARPI monotherapy. At a 36-month timepoint, those who maintain a prostate specific antigen (PSA) ≤ 0.2ng/mL will have the option to either discontinue treatment proceeding with active surveillance or continue on their ARPI until disease progression or intolerable toxicity. Patients who discontinue ARPI will resume ARPI and ADT when the PSA ≥ 2 ng/mL above the lowest PSA on two consecutive checks at least 1 month apart, there is evidence of progressive disease (PD) on conventional scans \[CT/MRI imaging per modified RECIST 1.1 or bone scan per Prostate Cancer Clinical Trials Working Group 3 (PCWG3)\], clinical symptoms of progression, or if the patient prefers to continue ARPI and ADT.

    Drug: Androgen Deprivation Therapy (ADT) · Drug: Androgen Receptor Pathway Inhibitor (ARPI) · Radiation: Prostate Radiation

  • Experimental
    High Risk Prostate Cancer

    High-risk patients will receive triplet therapy with ADT + ARPI + 6 cycles of docetaxel followed by 18-months of ADT + ARPI and then 12-month ARPI monotherapy. If a patient has high-risk disease but, based on the investigator's judgment, has contraindications to docetaxel or is deemed unsuitable for it, they will receive the same treatment regimen as other high-risk patients minus the docetaxel. Then at a 36-month timepoint, those who maintain a PSA ≤ 0.2ng/mL will have the option to either discontinue treatment with active surveillance or continue ARPI until disease progression or intolerable toxicity. Patients who discontinue ARPI will resume ARPI and ADT when the PSA ≥ 2 ng/mL above the lowest PSA (nadir) on two consecutive checks at least 1 month apart, there is evidence of progressive disease (PD) on conventional scans \[CT/MRI imaging per modified RECIST 1.1 or bone scan per PCWG3\], clinical symptoms of progression, or if the patient prefers to continue ARPI and ADT.

    Drug: Androgen Deprivation Therapy (ADT) · Drug: Androgen Receptor Pathway Inhibitor (ARPI) · Drug: Docetaxel

Interventions

  • DrugAndrogen Deprivation Therapy (ADT)

    ADT, Gonadotropin-releasing hormone (GnRH) agonist or antagonists, as prescribed by the treating physician.

  • DrugAndrogen Receptor Pathway Inhibitor (ARPI)

    Darolutamide is the preferred ARPI for this study; however, patients may receive abiraterone, apalutamide, or enzalutamide at the discretion of their oncologist and based on patient preference.

  • RadiationProstate Radiation

    prostate radiation, with or without radiation to metastatic sites

  • Docetaxel will be administered as prescribed by the treating physician.

    Also known as: Taxotere, Docivyx, Docefrez, BEIZRAY

06

What researchers measure

Primary outcomes

  1. Radiological progression-free survival (rPFS)

    rPFS is defined as the time from the first dose of systemic therapy for mCSPC to the first documented radiological progression in soft tissue or bone, based on CT, MRI, or NM bone scan, using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for soft-tissue metastases and Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases, or death from any cause.

    Time frame: 36 months

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from the date of treatment to death from any cause. OS at 5 years is defined as being alive at 5 years after starting of ADT.

    Time frame: 5 years

  2. rPFS using PSMA PET/CT scan combined with PSA response

    This is defined at the time from the first dose of systemic therapy for mCSPC to the time to progressive disease as measured by PSMA PET/CT scan (RECIP 1.0) combined with PSA response

    Time frame: 5 years

  3. Time to initiation of subsequent antineoplastic therapy

    Time to initiation of subsequent antineoplastic therapy is defined as the time from initiation of ADT to subsequent antineoplastic therapy for prostate cancer.

    Time frame: 5 years

  4. Disease progression within 5 years of starting ADT for mCSPC

    The number of patients with disease progression at 5 years

    Time frame: 5 years

  5. Symptomatic skeletal event free (SSE) survival

    SSE survival is defined as the time from first dose of systemic therapy for mCSPC to the first occurrence of SSE or death from any cause, whichever comes first. An SSE is defined as external beam radiation therapy (EBRT) to relieve skeletal symptoms, or new symptomatic pathologic bone fracture, or occurrence of spinal cord compression or tumor-related orthopedic surgical intervention, whichever comes first.

    Time frame: 5 years

  6. Time to pain progression

    Time from start date of ADT to the first date a subject experiences a pain progression. Pain will be assessed using the PEG Scale (Pain, Enjoyment, General Activity) Questionnaire

    Time frame: 5 years

  7. Adverse Events

    Number of patients with an AE that resulted in treatment discontinuation.

    Time frame: 5 years

  8. Quality-of-life changes per Functional Assessment of Cancer Therapy (FACT) Prostate Cancer Symptom Index - 17 (FACT-FPSI-17)

    Patients with changes to quality of life ans sexual function as measured by National Comprehensive Cancer Network- Functional Assessment of Cancer Therapy (FACT) Prostate Cancer Symptom Index - 17 Item Version (NCCN/FACT-FPSI-17). Score rage 0 to 68, a score of "0" is a severely symptomatic patient and the highest possible score is an asymptomatic patient.

    Time frame: 3 months, 6 months, 9 month, 1 year

  9. Quality-of-life changes per Brief Pain Inventory-Short Form (BPI-SF)

    Patients with changes to quality of life as measured by Brief Pain Inventory-Short Form (BPI-SF). Score range 0 to 10; a low score equals less pain severity and less pain interference, a higher score equals higher pain severity and interference.

    Time frame: 3 months, 6 months, 9 month, 1 year

  10. Development of osteoporosis

    The number of patients that develope osteoporosis within 5 years on study

    Time frame: 5 years

  11. Development of osteopenia

    The number of patients that develope osteopenia within 5 years on study

    Time frame: 5 years

  12. Prevalence of gynecomastia

    The number of patients who develop Grade 1 to 3 Gynecomastia;

    Time frame: 5 years

07

Study locations

1 site
  • Georgetown University Medical Center- Lombardi Comprehensive Cancer Center
    Washington D.C., District of Columbia 20007, United States
    • Paul Leger, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2032, 68 months later.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 68 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartEst.
Dec 2026was Aug 2026
Primary completionEst.
Aug 2032
CompletionEst.
Aug 2032
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Dec 2026
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Start date Aug 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07645326
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Dec 2026 (estimated)
Primary completion
Aug 2032 (estimated)
Completion
Aug 2032 (estimated)
Last update
Oct 6, 2026

Study contacts

Paul D Leger, MD
Contact
paul.d.leger@gunet.georgetown.edu
202-444-2223
Paul D Leger, MD
principal investigator · Georgetown University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion